Background and Aims: Various publications suggested that there is an association betweenCYP7A1single nucleotide polymorphisms (SNP) and a reduced response to statin therapy, but the results were inconsistent. This study aimed to collectively review these publications to appraise the effect of statins on cholesterol control in carriers ofCYP7A1variant alleles.Methods:PUBMED, Cochrane and EMBASE were searched systematically to identify reported studies on the lipid responses to statin treatment between carriers of the variant alleleversusthe non-variant allele ofCYP7A1SNPs. The change from baseline in lipid responses for all included studies were calculated using weighted mean differences (WMD) (with 95% confidence interval (CI)). A meta-analysis was conducted to pool results using either the random-effects model or the fixed effects model.Results:A total of 6 publications comprising of 1,686 subjects for the assessment of total cholesterol, LDL-C and HDL-C and 1,156 subjects for the assessment of triglycerides were included in the meta-analyses. Subjects who were non-carriers of aCYP7A1SNP (−204 A/C (rs3808607), −278 A/C (rs3808607) and rs8192875) had a greater reduction in total cholesterol (overall WMD -0.17, 95% CI -0.29, −0.06) and LDL-C levels (overall WMD -0.16, 95% CI -0.26, −0.05) as compared with subjects who borne the variant allele ofCYP7A1SNPs when administered a statin.Conclusion:The presence of variant allele ofCYP7A1SNPs may result in suboptimal control of total cholesterol and LDL-C levels as compared with individuals who do not carry the variant allele, when administered an equivalent dose of statin.